Adalimumab
Patients with hidradenitis suppurativa benefit when treatment combines adalimumab, surgery
Adalimumab accompanied by surgery significantly out-performed adalimumab monotherapy in the treatment of patients with moderate to severe hidradenitis suppurativa, according to a study.
Adalimumab plus methotrexate lowers treatment failure 2-fold in pediatric Crohn’s
Combination therapy with adalimumab plus low-dose methotrexate induced a two-fold reduction of treatment failure among pediatric patients with Crohn’s disease, according to research published in Gastroenterology.
FDA denies Alvotech’s application for Humira biosimilar candidate
The FDA has denied a biologics license application to Alvotech for AVT02, a high-concentration adalimumab biosimilar candidate, according to a press release from Teva Pharmaceutical Industries.
Benefits outweigh risks when switching biologics for rheumatoid arthritis
Patients with rheumatoid arthritis who achieve only a partial response with adalimumab demonstrate a low risk for worsened symptoms and a high likelihood of meaningful improvement when switching to sarilumab, according to data.
FDA approves citrate-free, high-concentration form of biosimilar Hyrimoz
The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, according to a press release from the manufacturer.
Longer adalimumab dose intervals improve infection risk, worsen remission rates in Crohn’s
Increasing adalimumab dose intervals reduced infection-related adverse events and costs in patients with Crohn’s disease, but also resulted in lower remission rates, researchers reported in The Lancet Gastroenterology & Hepatology.
More than 90% of GIs are ‘somewhat comfortable’ prescribing adalimumab biosimilars
Most gastroenterologists reported higher familiarity with adalimumab biosimilars and reported greater comfort levels in prescribing biosimilars than dermatologists or rheumatologists, according to a recent survey.
Few rheumatologists say economic benefits of biosimilars sufficient to warrant switching
Although most rheumatologists report they are comfortable with the idea of prescribing biosimilars, only approximately 18% think the economic benefits warrant switching their patients to one, according to a Cardinal Health survey.
‘Proactive education’ critical to preparing patients for likely biosimilar switch
DENVER — Proactively educating patients on biosimilar efficacy and cost-savings associated with their use can help reduce anxiety and bias if/when their insurance opts to switch, according to a presenter at the Crohn’s and Colitis Congress.
Adding TNF inhibitor, triple therapy to RA treatment improves vascular inflammation
In patients with active rheumatoid arthritis despite methotrexate use, adding either a TNF inhibitor or triple therapy with sulfasalazine and hydroxychloroquine improves vascular inflammation, according to data.